The company’s shares of confidence were underlined by an upgraded 2026 outlook, with Merck now expecting annual net sales of up to €21.4 billion and EBITDA pre of as much as €6.1 billion
The accrued data from the Phase 3 study suggest that the baseline characteristics of the enrolled patients are consistent with those observed in previous studies
Researchers reported that patients treated with the wearable system were discharged around five days earlier than those receiving standard hospital-based care
The company also confirmed that ABS-1230 has been accepted into the U.S. Food and Drug Administration’s Rare Disease Evidence Principles (RDEP) process
In the new study, scientists at the University of Virginia used gene-editing techniques to modify GLP-1 receptors in mice to make them more humanlike
The company highlighted a series of strategic moves during the year, including the acquisition of WOKADINE, marking its entry into the Rs. 648 Cr Povidone Iodine market
Bengaluru startup targets 100+ enterprise clients and global expansion as it aims to transform pharmaceutical sales, marketing, tenders, and distribution using AI agents
Strong export-led growth and improved profitability as the company focuses on CNS drug development and global regulatory footprint
Subscribe To Our Newsletter & Stay Updated
